Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly’s stock was down ...

While this adds competition to a market currently controlled by Eli Lilly LLY-2.84 % decrease; red down pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, ...

CHGCY believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s LLY oral obesity pill, orforglipron. Roche Holdings AG RHHBY is a major shareholder of Chugai, a Japanese ...